These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 24319188)

  • 1. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
    Lillicrap D
    Hematology Am Soc Hematol Educ Program; 2013; 2013():254-60. PubMed ID: 24319188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
    Lillicrap D
    Blood; 2013 Nov; 122(23):3735-40. PubMed ID: 24065240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on type 2B von Willebrand disease.
    Mikhail S; Aldin ES; Streiff M; Zeidan A
    Expert Rev Hematol; 2014 Apr; 7(2):217-31. PubMed ID: 24521271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the diagnosis and management of type 1 von Willebrand disease.
    Castaman G; Rodeghiero F
    Expert Rev Hematol; 2011 Feb; 4(1):95-106. PubMed ID: 21322782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology, diagnosis, and management of von Willebrand disease in India.
    Ghosh K; Shetty S
    Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetic basis of von Willebrand disease.
    Goodeve AC
    Blood Rev; 2010 May; 24(3):123-34. PubMed ID: 20409624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
    Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
    Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and management of von Willebrand disease in Australia.
    Favaloro EJ; Bonar R; Favaloro J; Koutts J
    Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
    Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
    J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of inherited von Willebrand disease in 2007.
    Federici AB; Mannucci PM
    Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat type 2B von Willebrand disease.
    Kruse-Jarres R; Johnsen JM
    Blood; 2018 Mar; 131(12):1292-1300. PubMed ID: 29378695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.